BMS-986218

non-fucosylated anti-CTLA-4 antibody · Bristol Myers Squibb

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for BMS-986218, covering 2025-04-24 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies [Phase 1, Phase 2]

See pricing